Iyo Bank Ltd. Buys 4,140 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Iyo Bank Ltd. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 15,049 shares of the medical research company’s stock after acquiring an additional 4,140 shares during the period. Thermo Fisher Scientific makes up 2.4% of Iyo Bank Ltd.’s investment portfolio, making the stock its 16th biggest position. Iyo Bank Ltd.’s holdings in Thermo Fisher Scientific were worth $7,488,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $25,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $30,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific in the first quarter worth $35,000. Navigoe LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $37,000. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $52,340,824.30. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,400 shares of company stock worth $8,345,792. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $462.59 on Tuesday. The stock has a market cap of $174.68 billion, a PE ratio of 26.75, a price-to-earnings-growth ratio of 2.46 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The firm’s 50-day simple moving average is $428.13 and its two-hundred day simple moving average is $461.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Wall Street Analyst Weigh In

TMO has been the subject of several recent analyst reports. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.